University of Florida

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Florida sits in the top decile of US sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count).

1,106 total trials 170 currently recruiting 754 completed early-phase tilt top decile by trial count

University of Florida: 1,106 sponsored US clinical trials, 170 recruiting.

University of Florida sponsors 1,106 registered US clinical trials on ClinicalTrials.gov, 170 of them currently recruiting, and 754 completed. 103 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 17 trials.

Top-decile sponsor footprint

University of Florida ranks in the top decile of sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

754 of 855 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,106 total, page 4 of 23

RECRUITING Phase 4

Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients

NCT04281017

RECRUITING

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

NCT01484678

RECRUITING NA

Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries

NCT04322370

RECRUITING NA

Dual Lead Thalamic Deep Brain Recording (DBR)-DBS Interface for Closed Loop Control of Severe Essential Tremor

NCT04212780

RECRUITING NA

Pilot Intervention With Near Infrared Stimulation

NCT03551392

RECRUITING NA

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

NCT03886961

RECRUITING

PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing

NCT03175302

RECRUITING NA

Non-invasive Nerve Stimulation for PTSD and Sleep

NCT03170440

RECRUITING Early Phase 1

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

NCT02621944

RECRUITING

Multi-center Evaluation of the Clinical Utility of ESD in the Western Population

NCT02989818

RECRUITING

Biomarkers in Friedreich's Ataxia

NCT02497534

RECRUITING

Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

NCT02368041

RECRUITING NA

Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury

NCT02577731

RECRUITING

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642

RECRUITING

Clinical Orthopaedic Data Bank (Acute and Chronic)

NCT00411060

RECRUITING NA

Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

NCT02216500

RECRUITING

Florida Center for Brain Tumor Research

NCT00811148

RECRUITING

Immune Function and the Progression to T1D

NCT05899439

RECRUITING

Biomechanics/Motion Analysis Laboratory Data Bank

NCT00160771

RECRUITING

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

NCT00500123

ACTIVE NOT RECRUITING Phase 2

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

NCT07220720

ACTIVE NOT RECRUITING Phase 1

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

NCT07031765

ACTIVE NOT RECRUITING NA

Sweet Corn and Carotenoids

NCT06892444

ACTIVE NOT RECRUITING Phase 1

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898

ACTIVE NOT RECRUITING Phase 1

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)

NCT06946680

ACTIVE NOT RECRUITING Phase 1

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

NCT05660408

ACTIVE NOT RECRUITING NA

Corn Glycemic Index

NCT06847815

ACTIVE NOT RECRUITING NA

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

NCT06565546

ACTIVE NOT RECRUITING NA

The Feasibility of the Pray Until Something Happens (PUSH) Intervention-OUTPATIENT

NCT06580067

ACTIVE NOT RECRUITING Phase 1

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

NCT06389591

ACTIVE NOT RECRUITING Phase 1

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

NCT06254326

ACTIVE NOT RECRUITING NA

The Efficacy of Biplane Versus Single Plane Ultrasound in Facilitating Caudal Epidural Anesthesia in Pediatric Patients.

NCT06319989

ACTIVE NOT RECRUITING Phase 1

A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)

NCT06415461

ACTIVE NOT RECRUITING

Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

NCT06063213

ACTIVE NOT RECRUITING NA

Clinical Trial to Assess the Efficacy of Reducing the Aligners' Wear Protocol

NCT05905224

ACTIVE NOT RECRUITING Phase 1

Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia

NCT05892770

ACTIVE NOT RECRUITING NA

MOS Prebiotic Potential in Older Adults

NCT05939336

ACTIVE NOT RECRUITING Phase 1

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

NCT05353530

ACTIVE NOT RECRUITING NA

Fasting ENHANCE Pilot Study

NCT05732935

ACTIVE NOT RECRUITING NA

The Fuel and Rhythm (FAR) Phase 2 Study

NCT05482711

ACTIVE NOT RECRUITING NA

Digital Motivational Behavioral Economic Intervention to Reduce Risky Drinking Among Community-Dwelling Emerging Adults

NCT05443750

ACTIVE NOT RECRUITING NA

CHOICES3: Sickle Cell Disease Parenting CHOICES

NCT05292781

ACTIVE NOT RECRUITING Phase 3

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172

ACTIVE NOT RECRUITING NA

Trial of Preemptive Pharmacogenetics in Underserved Patients

NCT05141019

ACTIVE NOT RECRUITING Phase 2

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

NCT05120284

ACTIVE NOT RECRUITING Phase 1

Adenosine 2A Receptor Antagonism and AIH in ALS

NCT05377424

ACTIVE NOT RECRUITING NA

Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression

NCT05371041

ACTIVE NOT RECRUITING Phase 2

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

NCT05081882

ACTIVE NOT RECRUITING

Clinical Markers of Dysphagia in Cardiac Surgical Patients

NCT05304416

ACTIVE NOT RECRUITING NA

Frequent Standardized Oral Care to Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit

NCT05167318

← Previous Page 4 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 123
Phase 2 109
Phase 3 13
Phase 4 90

What is open in the University of Florida pipeline

170 recruiting of 1,106 indexed (15% open); 754 completed (68%).

Phase mix: 103 late (III/IV) vs 232 early (I/II) (early-phase heavy).

Top condition: Coronary Artery Disease (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Florida: open-pipeline peers nationwide

Peers matched on 1,106 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of FloridaUniversity of North Carolina, Chapel HillWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,106 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Florida page

1,106 registered trials is a research-attention snapshot, not an endorsement of University of Florida or any single study.

  • 170 of University of Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Artery Disease is the condition University of Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Florida pipeline card: 1,106 registered trials from official public datasets.Report a data error.